Original Article

Is medulloblastoma associated with systemic immunomodulation? – A comparative analysis of preoperative inflammatory markers

Ravi Sharma¹, Varidh Katiyar¹, Hitesh Gurjar¹, Mehar Sharma², Revanth Goda¹, Zainab Vora³

Departments of ¹Neurosurgery, ²Pathology, and ³Radio diagnosis, All India Institute of Medical sciences, CNC, AIIMS, New Delhi, India.

E-mail: Ravi Sharma - aiims.ravisharma@gmail.com; *Hitesh Gurjar - hiteshgurjar@gmail.com; Varidh Katiyar - katiyar.varidh@gmail.com; Mehar Sharma - sharmamehar@yahoo.co.in; Revanth Goda - revanth2k7@gmail.com; Zainab Vora - zainab8@gmail.com

INTRODUCTION

Adult brain tumors have been found to be associated with systemic modulation of the immune system.[4] In fact, pathological evaluation reveals important role of host leukocytes and macrophages in influencing the progression of neoplastic pathologies.[6,10,19] Angiogenesis,
which is an important factor to sustain the growth of neoplasms, is also dependent on inflammatory cytokines and growth factors. Tumor-associated neutrophils have been proposed to play little antitumor role, if any. On the contrary, they are associated with progression of tumor and degeneration to a higher grade. Neutrophil counts (NCs) and neutrophil-lymphocyte ratios (NLRs) are found to be correlated to the prognosis of patients in many different malignancies. On the basis of these findings, there has been a recent surge in interest regarding the changes in the systemic inflammatory markers in the brain tumors as well. Although brain is an immunologically privileged site, it has been found in several studies that NC, NLR, and other hematological inflammatory markers are associated with the grade of glioma in adult patients. NLR has been shown to not only correlate with the probability of a higher grade of tumor but it can also be used as a prognostic marker with higher NLR values associated with decreased survival. A few authors have also observed gliomas to be associated with immunosuppression. Lymphopenia is a contributing factor in the high NLR observed in glioblastoma patients apart from raised NC.

Although the pediatric population is different in terms of the common types and location of brain tumors, few recent studies have shown that the immunological parameters are altered in the pediatric brain tumors as well. NLR, mean platelet volume (MPV), and total leukocyte count (TLC) were found to be associated with the presence of intracranial tumor in pediatric population.

On this background, we attempt to compare these inflammatory markers among children with medulloblastoma (MB), pilocytic astrocytoma (PA), and healthy controls (HCs). We also aim to assess the efficacy of various inflammatory parameters and their combinations for differentiating medulloblastoma from pilocytic astrocytoma and healthy controls.

**MATERIALS AND METHODS**

**Study design**

The electronic medical records of pediatric population (<18 years) with biopsy-proven posterior fossa medulloblastoma and pilocytic astrocytoma operated at the Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India, from January 2012 to January 2018 were collected and retrospectively analyzed. Patients who had recurrent tumor, had received preoperative chemotherapy and radiotherapy, preoperative hormonal replacement including glucocorticoids, history of infection or fever at the time of admission, history of autoimmune or hematological disease at the time of admission, history of serious hepatic, renal or cardiac dysfunction at the time of admission, history of medications which can alter blood parameters, or whose complete data on preoperative blood counts and serum albumin levels were not available were excluded from the study. Informed written consent was obtained from the guardian/parents of the child. For the control group, we included children who came to annual health check-up at the periphery screening centers of our institute with noninfectious/nonmalignant conditions such as lipomas and scoliosis. This study was approved by the Institutional Ethics Committee.

**Data collection**

Information regarding the demographic and disease characteristics, including age, sex, and histopathology diagnosis, were retrieved from the hospital medical records and electronic database. Within 1 week before surgery, routine preoperative blood investigations were done. The TLC, NC, ALC, and PC were collected from the routine blood test, and albumin levels were collected from the hepatic function test. Other composite variables such as preoperative NLR (quotient of NC to LC), dNLR (quotient of NC to [TLC–NC]), PLR (ratio of PC to LC), and PNI (serum albumin (g/L)) + 5 x total lymphocyte count) were calculated as described.

**Statistical analysis**

Statistical analysis was performed using the SPSS version 20. Initially, normality of the distribution of the variables was analyzed using the Kolmogorov–Smirnov test. Since almost all variables deviated significantly from normality, nonparametric statistics were used for estimates of central tendency and hypothesis testing. Continuous variables were presented as median with interquartile range (IQR). For comparison between groups, the Mann–Whitney U-test was used. NLR, dNLR, PLR, and PNI of MB group were compared with pilocytic astrocytoma and healthy controls. The diagnostic performance of NLR, dNLR, PLR, PNI, and their combinations was assessed by values of the area under the curve (AUC) obtained from the receiver operating characteristic (ROC) curve. Cutoff points were estimated using ROC curves for the variables which demonstrated significant diagnostic accuracy using the maximum Youden index as the criteria. Throughout the analysis, a two-tailed P < 0.05 was considered statistically significant.

**RESULTS**

**Study population**

A total of 53 patients with medulloblastoma, 66 with pilocytic astrocytoma located in the posterior fossa and a control group of 75 healthy children were included in the final analysis. The demographic characteristics for the study subjects are presented in Table 1. The age of patients with
medulloblastoma ranged from 2.5 to 17 years, with median age being 8 years. The median age for patients with pilocytic astrocytoma and healthy controls was also 8 years. The sex distribution was also similar in all the three groups.

Comparison of preoperative inflammatory markers in medulloblastoma, pilocytic astrocytoma, and healthy controls

The preoperative inflammatory markers and comparisons between medulloblastoma, pilocytic astrocytoma, and healthy controls are detailed in Table 1. Patients with medulloblastoma had significantly higher NLR, dNLR, PLR, and platelet counts compared with healthy controls. Similarly, patients with medulloblastoma were found to have higher NLR, dNLR, PLR, and platelet counts compared with pilocytic astrocytoma. ALC was significantly lower in medulloblastoma group as compared to healthy controls but not with pilocytic astrocytoma. However, there were no statistically significant differences in various preoperative inflammatory markers between the pilocytic astrocytoma and healthy control groups.

Evaluation of diagnostic efficacy of preoperative inflammatory markers and their combinations in patients with medulloblastoma versus healthy controls

For individual parameters, NLR and dNLR demonstrated maximum diagnostic accuracy in distinguishing patients with medulloblastoma from healthy controls, with AUC of ROC curve analysis of 0.783 and 0.848, respectively [Table 2, Figure 1]. Cutoffs of 2.45 for NLR and 1.47 for dNLR

| Characteristic | MB group (n=53) | PA group (n=66) | HCs (n=75) | P value |
|----------------|----------------|----------------|------------|---------|
| Age            | 8 (6–10)       | 8 (6–10)       | 8 (5–10)   | *0.651  |
| Males (%)      | 36 (67.9%)     | 34 (51.5%)     | 40 (53.3%) | *0.092  |
| TLC (10⁹/L)    | 8.4 (6.2–10.2) | 8.75 (5.9–11)  | 8.8 (6.4–11) | *0.756 |
| ANC (10⁹/L)    | 5.42 (4.15–6.66) | 5.06 (3.08–6.38) | 4.86 (3.71–6.48) | *0.198 |
| ALC (10⁹/L)    | 1.18 (0.9–1.55) | 1.38 (0.95–1.75) | 1.43 (0.99–1.81) | *0.148 |
| PC (10⁹/L)     | 217 (178–335)  | 210 (156–239)  | 210 (156–239) | *0.045 |
| Albumin (g/L)  | 42 (38–48)     | 45 (37–48)     | 44 (36–48)  | *0.531  |
| NLR            | 2.8 (2.5–3.1)  | 2.1 (1.8–2.8)  | 1.9 (1.6–2.6) | *<0.001 |
| dNLR           | 1.78 (1.63–2.03) | 1.33 (1.22–1.5) | 1.33 (1.22–1.44) | *<0.001 |
| PLR            | 183.52 (123.27–301.9) | 145.52 (103.5–205.27) | 141.97 (101.07–234.03) | *0.036 |
| PNI            | 47.88 (43.5–54.19) | 50.59 (43.37–56.56) | 49.17 (42.5–56.77) | *0.37 |

*MB versus PA, # MB versus HC, SPA versus HC. All values are reported as median (interquartile range). MB: Medulloblastoma, PA: Pilocytic astrocytoma, HC: Healthy controls, NLR: Neutrophil-lymphocyte ratio, dNLR: Derived neutrophil-lymphocyte ratio, PLR: Platelet-lymphocyte ratio, ALC: Absolute lymphocyte count, TLC: Total leukocyte count
were found to have best diagnostic accuracy in distinguishing medulloblastoma and healthy controls with Youden index of 0.422 and 0.59, respectively [Table 3]. Similar to the differences noted in comparison between medulloblastoma and healthy controls, NLR and dNLR were the only two individual parameters which performed reasonably well for

**Table 2:** Diagnostic efficacy of NLR, dNLR, PLR, PNI, ALC, and their combinations in differentiating subjects with medulloblastoma, pilocytic astrocytoma, and healthy controls.

| Characteristic | MB versus HC AUC (95% CI) | PA versus HC AUC (95% CI) | MB versus PA AUC (95% CI) |
|---------------|---------------------------|---------------------------|---------------------------|
| NLR           | 0.783 (0.705–0.861)       | 0.541 (0.445–0.636)       | 0.767 (0.683–0.851)       |
| dNLR          | 0.848 (0.776–0.919)       | 0.515 (0.419–0.611)       | 0.851 (0.778–0.924)       |
| PLR           | 0.627 (0.53–0.725)        | 0.52 (0.424–0.616)        | 0.612 (0.511–0.713)       |
| PNI           | 0.462 (0.361–0.562)       | 0.507 (0.411–0.603)       | 0.452 (0.348–0.556)       |
| ALC           | 0.604 (0.506–0.702)       | 0.527 (0.431–0.623)       | 0.577 (0.474–0.680)       |
| NLR + dNLR    | 0.856 (0.788–0.923)       | 0.549 (0.453–0.645)       | 0.86 (0.79–0.93)          |
| NLR + PLR     | 0.789 (0.713–0.866)       | 0.535 (0.44–0.631)        | 0.764 (0.68–0.848)        |
| NLR + PNI     | 0.782 (0.704–0.86)        | 0.535 (0.44–0.631)        | 0.767 (0.683–0.851)       |
| dNLR + PLR    | 0.842 (0.771–0.912)       | 0.513 (0.417–0.609)       | 0.849 (0.776–0.921)       |
| dNLR + PNI    | 0.838 (0.763–0.914)       | 0.507 (0.411–0.603)       | 0.841 (0.764–0.919)       |
| PLR + PNI     | 0.631 (0.535–0.727)       | 0.528 (0.432–0.623)       | 0.6 (0.497–0.702)         |
| NLR + dNLR + PLR | 0.855 (0.788–0.921) | 0.542 (0.446–0.637) | 0.856 (0.786–0.927) |
| NLR + PLR + PNI | 0.788 (0.711–0.865) | 0.535 (0.439–0.631) | 0.766 (0.682–0.85) |
| NLR + PNI + dNLR | 0.854 (0.786–0.922) | 0.551 (0.455–0.647) | 0.856 (0.784–0.929) |
| dNLR + PLR + PNI | 0.844 (0.774–0.913) | 0.524 (0.428–0.62) | 0.849 (0.776–0.921) |
| NLR + dNLR + PLR + PNI | 0.855 (0.79–0.921) | 0.539 (0.443–0.635) | 0.855 (0.785–0.926) |

NLR: Neutrophil-lymphocyte ratio, dNLR: Derived neutrophil-lymphocyte ratio, PLR: Platelet-lymphocyte ratio, ALC: Absolute lymphocyte count.

**Table 3:** Diagnostic cutoff and sensitivity-specificity analysis of NLR, dNLR, and their combinations in differentiating subjects with medulloblastoma, pilocytic astrocytoma, and healthy controls.

| Diagnostic marker | MB versus HC | MB versus PA |
|-------------------|-------------|-------------|
|                    | Cutoff      | Sensitivity (%) | Specificity (%) | Cutoff      | Sensitivity (%) | Specificity (%) |
| NLR                | 2.45        | 75.5         | 66.7           | 2.45        | 75.5         | 66.7           |
| dNLR               | 1.47        | 83.0         | 76.0           | 1.53        | 81.1         | 81.8           |
| NLR + dNLR (x)     | 0.407       | 81.1         | 78.7           | 0.428       | 79.2         | 78.8           |

Logit(x) = 0.978 x NLR + 3.014 x dNLR – 7.548

Logit(x) = 0.711 x NLR + 3.54 x dNLR - 7.596

MB: Medulloblastoma, PA: Pilocytic astrocytoma, HC: Healthy controls, NLR: Neutrophil-lymphocyte ratio, dNLR: Derived neutrophil-lymphocyte ratio

**Figure 1:** Receiver operating characteristic curves for individual variables for distinguishing between (a) medulloblastoma and healthy controls, (b) pilocytic astrocytoma and healthy controls, and (c) medulloblastoma and pilocytic astrocytoma.
distinguishing patients with medulloblastoma from those with pilocytic astrocytoma, with AUC of 0.767 and 0.851, respectively [Table 2, Figure 1] and at the cutoffs of 2.45 for NLR and 1.53 for dNLR had Youden index of 0.422 and 0.629, respectively [Table 3]. As previously, combinations of NLR and dNLR performed only marginally better than individual variables with AUC being 0.856 for medulloblastoma versus healthy controls and 0.86 for medulloblastoma versus pilocytic astrocytoma. Although ALC was found to be significantly lower in medulloblastoma group, it had a low AUC of 0.604 on ROC curve analysis [Table 2]. None of the other combinations performed any better NLR + dNLR and were not analyzed further. No significant difference was observed in any of the inflammatory markers between the pilocytic astrocytoma and healthy controls group. The ROC curves for the significant individual and combination variables are shown in Figure 2.

**Statistical prediction model for medulloblastoma**

The performance of different combinations of all the inflammatory parameters as a diagnostic marker for distinguishing among medulloblastoma, pilocytic astrocytoma, and healthy controls group was assessed by constructing logistic regression model followed by their ROC curve analysis. Only the combination of NLR and dNLR had substantial value over individual variables to predict medulloblastoma in comparison to pilocytic astrocytoma and healthy controls, as discussed previously. The equations describing the logistic regression model to combine NLR and dNLR for medulloblastoma versus pilocytic astrocytoma and medulloblastoma versus healthy controls group are given in Table 3.

**DISCUSSION**

There is recent surge of interest in the relationship between inflammation and tumor development and progression. In fact, various blood inflammatory markers have been shown to be related to various malignancies. For example, preoperative NLR and PLR have been shown to help in early detection and prognosis in patients with colorectal cancer. Recently, such hematological parameters like NLR have been investigated not only as a predictive marker for the presence and grade of glial tumors but also as a prognostic marker in GBM. Raised NLR is found to be associated with poor prognosis in patients with GBM. Zheng et al have even investigated the correlation between the hematological parameters with histopathological grade and found that NLR and dNLR are predictive of the WHO grade of glioma. Similarly, Han et al observed prognostic significance of PLR in glioma patients.

In the light of these findings, several researchers have investigated the role of these blood markers in pediatric brain tumors as well. Tumturk et al conducted a retrospective study of patients <3 years of age and found correlation of preoperative WBC count, NLR and MPV with the presence of CNS tumors. However, they included a wide range of malignant and benign tumors, and no association was found with the different histological types of pediatric brain tumors.

However, in another recent study conducted by Patel et al, absolute lymphopenia and raised NLR was found in patients with medulloblastoma when compared with pilocytic astrocytoma. The authors attributed the lymphopenia to tumor-induced systemic immunosuppression. It is noteworthy that there were only 16 patients in each group in this study and ROC curve analysis was not done to define cutoffs for the same. In our study, we also found raised NLR to be associated with medulloblastoma both in comparison to pilocytic astrocytoma and healthy controls. However, we found significant lymphopenia in the medulloblastoma group when compared to healthy controls but not with pilocytic astrocytoma in contrast to Patel et al who found ALC to be different between medulloblastoma and

---

*Figure 2: Receiver operating characteristic curves for significant individual and combination variables for distinguishing between (a) medulloblastoma and healthy controls and (b) medulloblastoma and pilocytic astrocytoma.*
pilocytic astrocytoma. Thus, raised NLR, at least partially due to lymphopenia, seems to indicate systemic immune suppression in children with medulloblastoma.

Wilson et al.\cite{22} have attempted to evaluate the relation between the preoperative NC and NLR and the grade of different pediatric intracranial tumors. They included all the supratentorial and infratentorial tumors and compared the NC and NLR values among the low and high grades of all tumors collectively. Although this fails to provide significant clinical information for treatment or prognostication of any individual tumor type, it has provided great insight into the immunological alterations induced by neoplastic pathologies even at an immune privileged site like brain. They found that NC could predict the histological grade of tumors and though NLR was also correlated, it fell short of statistical significance. We have attempted to evaluate these parameters, specifically in the most common high-grade and low-grade pediatric brain tumors which are medulloblastoma and pilocytic astrocytoma, respectively, and compare them with that of healthy controls. We have found that the primary factor leading to raised NLR is decreased in the ALC. The probable mechanism behind tumor induced lymphopenia is secretion of immunosuppressive cytokines such as IL-10, IL-2, and TGF-β.\cite{11}

We analyzed the diagnostic efficiency of the various markers using ROC curves and found NLR and dNLR to be the only significant factor that can accurately predict medulloblastoma vis-à-vis pilocytic astrocytoma or healthy controls. ALC had considerably less accuracy with maximum Youden index of only 0.236 to distinguish medulloblastoma from healthy controls, though it was found to be significantly different. We observed that the correlation of NLR and dNLR could primarily be ascribed to neutrophilia rather than lymphopenia in our sample. NLR cutoffs of 2.45 and 2.45 and dNLR cutoffs of 1.47 and 1.53 had a good predictive accuracy for medulloblastoma when compared to pilocytic astrocytoma or healthy controls, respectively, in the pediatric population. Out of the combined markers, only NLR and dNLR combination was found to have significant predictive value. Although no other hematological marker was found to be of value in our study, their relevance cannot be ruled out based on the existing literature. Although Patel et al.\cite{18} did not do ROC curve analysis to identify the accuracy and appropriate cutoffs of NLR and ALC to predict medulloblastoma, their positive findings certainly lay ground for future investigation of the same. A prospective study with larger sample size must be done to not only accurately identify the significant variables but also to establish the diagnostic cutoffs for the same. The sensitivity and specificity of individual and combined parameters must be defined for this finding to be of clinical relevance. Further, the pathophysiological mechanisms behind these immunological perturbations must be studied in detail to elucidate its cause and effect relationship with tumor development and progression.

This study suffers from a few limitations. The most important drawback of the study being the symptomatology of these tumors commonly being vomiting and the treatment patient received for vomiting which possibly can affect immunological status of the patient, but we tried to exclude the patients who had a history of infection or who had received antibiotics before admission. The other drawbacks of the study are that the sample size of the study was small and this might have been the reason that a few markers failed to show significant correlation. This was a unicentric retrospective case–control study, in which we attempted to eliminate the possible sources of bias. However, large prospective studies with stringent selection criteria to eliminate bias are needed to verify the findings and provide a more accurate estimation of the diagnostic accuracy and cutoffs of these parameters. Considering the difference in the behavior of various molecular subtypes of medulloblastoma, it would be interesting to note the efficacy of these parameters in differentiating these subtypes. We did not include this analysis as this information was not available for some of our patients and the remaining number was too small to be of any statistical value. We have also not analyzed the long-term outcomes of the patients and thus the possible role of the parameters as a prognostic marker due to lack of follow-up data of the patients.

Apart from these limitations, we would like to discuss the clinical relevance of our study. Although the role of these biomarkers has been extensively studied in the adult glioblastoma patients, there is not much literature on the most common pediatric high-grade tumor, medulloblastoma. There is a study evaluating all the pediatric intracranial SOLs and evaluating the role of these parameters in predicting grade of these tumors irrespective of the histological type of tumor.\cite{22} Another study has evaluated the role of these parameters in medulloblastoma with respect to pilocytic astrocytoma but not with healthy controls.\cite{18} Furthermore, the authors did not evaluate the diagnostic accuracy and cutoffs for the significant factors identified in their study, probably because of small sample size, which would have been of a more direct clinical importance. Thus, ours is the first study which evaluates the role of immunological parameters in predicting medulloblastoma with respect to both pilocytic astrocytoma and healthy controls and also attempts to provide ROC curve analysis to assess diagnostic efficiency and cutoffs of the factors found to be significant.

**CONCLUSION**

The current evidence strongly suggests the interrelationship between immunological alterations and the pathogenesis and progression of medulloblastoma. It seems that NLR and dNLR can complement the imaging features in diagnosis of medulloblastomas in children similar to GBM in adults. However, the quantitative details of these findings and the underlying pathophysiologic mechanisms have not been
clearly elucidated. Our study gives an important directive for future research in the involvement of immune system and prognostic value of these factors in medulloblastoma patients.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Baecher-Allan C, Anderson DE. Regulatory cells and human cancer. Semin Cancer Biol 2006;16:98-105.
2. Bambury RM, Teo MY, Power DG, Yusuf A, Murray S, Battley JE, et al. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol 2013;114:149-54.
3. Bhatti I, Peacock O, Lloyd G, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: Neutrophil-lymphocyte ratio versus platelet-lymphocyte ratio. Am J Surg 2010;200:197-203.
4. Dagistan Y, Dagistan E, Gitisi V. Evaluation of simple blood inflammatory markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: Neutrophil-lymphocyte ratio versus platelet-lymphocyte ratio. J Neurooncol 2013;114:149-54.
5. Das S, Marsden PA. Angiogenesis in glioblastoma. N Engl J Med 2013;369:1561-3.
6. Fossati G, Ricevuti G, Edwards SW, Dalton A, Rossi ML. Neutrophil infiltration into human gliomas. Acta Neuropathol 1999;98:349-54.
7. Garcea G, Ladwa N, Neil CP, Metcalfe MS, Dennison AR, Berry DP. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg 2011;35:686-72.
8. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008;32:1757-62.
9. Gustafson MP, Lin Y, New KC, Bulur PA, O’Neill BP, Gastineau DA, et al. Systemic immune suppression in glioblastoma: The interplay between CD14+ HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol 2010;12:631-44.
10. Han S, Zhang C, Li Q, Dong J, Liu Y, Huang Y, et al. Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer 2014;110:2560-8.
11. Jia J, Zheng X, Chen Y, Wang L, Lin L, Ye X, et al. Stage-dependent changes of preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in colorectal cancer. Tumour Biol 2015;36:9319-25.
12. Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 2011;104:504-10.
13. Kang MH, Go SI, Song HN, Lee A, Kim SH, Kang JH, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer 2014;111:452-60.
14. Kawata A, Uey Y, Hosokawa M, Uchino J, Kobayashi H. Tumor-infiltrating lymphocytes and prognosis of hepatocellular carcinoma. Jpn J Clin Oncol 1992;22:256-63.
15. Kilincalp S, Coban S, Akinci H, Hamamci M, Karahmet F, Coskun Y, et al. Neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and mean platelet volume as potential biomarkers for early detection and monitoring of colorectal adenocarcinoma. Eur J Cancer Prev 2015;24:328-33.
16. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 2009;16:614-22.
17. McNamara MG, Lwin Z, Jiang H, Templeton AJ, Zadeh G, Bernstein M, et al. Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. J Neurooncol 2014;117:147-52.
18. Patel S, Wang S, Snuderl M, Karajannis MA. Pre-treatment lymphopenia and indication of tumor-induced systemic immunosuppression in medulloblastoma. J Neurooncol 2018;136:541-4.
19. Rutledge WC, Kong J, Gao J, Gutman DA, Cooper LAD, Appin C, et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res 2013;19:4951-60.
20. Sowers JL, Johnson KM, Conrad C, Patterson JT, Sowers LC. The role of inflammation in brain cancer. Adv Exp Med Biol 2014;816:75-105.
21. Tumturk A, Ozdemir MA, Per H, Unal E, Kucuk A, Ulutabanca H, et al. Pediatric central nervous system tumors in the first 3 years of life: Pre-operative mean platelet volume, neutrophil/lymphocyte count ratio, and white blood cell count correlate with the presence of a central nervous system tumor. Childs Nerv Syst 2017;33:233-8.
22. Wilson JR, Saeed F, Tyagi AK, Goodden JR, Sivakumar G, Battley JE, et al. Tumour-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res 2013;19:4951-60.
23. Zheng S, Huang J, Chen M, Wang B, Ou Q, Huang S. Diagnostic value of preoperative inflammatory markers in patients with glioma: A multicenter cohort study. J Neurosurg 2018;129:583-92.